Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Progression-free Survival
100%
Adrenocortical Carcinoma
100%
Rare Tumors
100%
PD-1 Blockade
100%
Basket Trial
100%
Immune-related
75%
Partial Response
75%
Stable Disease
75%
Ipilimumab
75%
Nivolumab
75%
Overall Survival
50%
Response Evaluation Criteria in Solid Tumors (RECIST)
50%
Prednisone
25%
Response Rate
25%
Disease Progression
25%
Adverse Events
25%
Hepatic Dysfunction
25%
Median Overall Survival
25%
Treatment Delay
25%
Common Cancers
25%
Treatment-related Adverse Events
25%
Rash
25%
Clinical Benefit
25%
Adrenal Insufficiency
25%
Phase II Clinical Trial
25%
Two-stage Design
25%
Immune Toxicity
25%
Long Progression-free Survival
25%
National Clinical Trials Network
25%
Clinical Benefit Rate
25%
Therapy Discontinuation
25%
Rare Cancer
25%
Anti-CTLA-4
25%
Immune-related Adverse Events
25%
Adrenocortical Cancer
25%
Medicine and Dentistry
Progression Free Survival
100%
Adrenal Cortex Carcinoma
100%
Rare Tumor
100%
Overall Survival
60%
Ipilimumab
60%
Nivolumab
60%
Diseases
60%
Clinical Trial
40%
Adverse Event
40%
Cancer
40%
Malignant Neoplasm
20%
Liver Dysfunction
20%
Immunotherapy
20%
Disease Exacerbation
20%
Exanthem
20%
Deterioration
20%
N [bis(1 Aziridinyl)phosphinyl] 4 Iodobenzamide
20%
Prednisone
20%
Adrenal Insufficiency
20%
CTLA-4
20%
Therapy Delay
20%
Immune-Related Adverse Events
20%
Pharmacology, Toxicology and Pharmaceutical Science
Progression Free Survival
100%
Adrenal Cortex Carcinoma
100%
Adverse Event
60%
Overall Survival
60%
Nivolumab
60%
Ipilimumab
60%
Diseases
60%
Clinical Trial
40%
Prednisone
20%
Neoplasm
20%
Malignant Neoplasm
20%
N [bis(1 Aziridinyl)phosphinyl] 4 Iodobenzamide
20%
Disease Exacerbation
20%
Immunotherapy
20%
Rash
20%
Deterioration
20%
Liver Dysfunction
20%
Adrenal Insufficiency
20%
Cytotoxic T Lymphocyte Antigen 4
20%